
Intellia Therapeutics Update: Insider Buys, Institutional Muscle & Phase 3 Momentum
Intellia Therapeutics (NTLA) is up 20%, insiders are buying, ARKK and Baker Bros are holding or adding, and Phase 3 trials are moving faster than expected. Here’s why CRISPR medicine may be ready for prime time — or another plot twist.
Tags:
ARKK,
ARKK Fund,
ATTR Amyloidosis,
Baker Bros,
Biotech,
Biotech Investing,
Biotech Investments,
Biotech Partnerships,
Biotech Stocks,
Biotechnology,
Biotechnology Innovation,
Cathie Wood,
Cathie Wood Stocks,
CRISPR,
CRISPR Gene Editing,
Fun biotech,
Funanc1al,
Funanc1al Contrarian Plays,
Funanc1al Insider Series,
Funanc1al Stocks to Watch,
FUNanc1alEdge,
funanc1alstocks,
gene editing,
HAE,
High Risk High Reward,
Intellia,
Intellia Therapeutics,
investing humor,
NTLA,
Phase 3 biotech,
Regeneron,
Stocks & Fun
Quick links
Search
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.